Close

vTv Therapeutics (VTVT) Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. TSLA
2. META
3. ENPH
4. TXN
5. BA
6. SPOT
7. IBM
8. V
9. HCP
10. KMB


Go back to vTv Therapeutics (VTVT) Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

September 23, 2021 4:30 PM EDT

HPP737 exhibited favorable safety and tolerability profile, with no dose limiting gastrointestinal side effects

Results build on data from previous multiple ascending dose study and support advancement of HPP737 into Phase 2 in moderate to severe psoriasis.

Successful pre-IND meeting with U.S. Food and Drug Administration Division of Dermatology and Dentistry supports planned IND submission for a Phase 2 study in moderate to severe psoriasis.

HIGH POINT, N.C., Sept. 23, 2021 (GLOBE NEWSWIRE) --... More